# Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

> **NCT01673009** · PHASE2 · COMPLETED · sponsor: **Indiana University** · enrollment: 36 (actual)

## Conditions studied

- Neurofibromatosis

## Interventions

- **DRUG:** Gleevec

## Key facts

- **NCT ID:** NCT01673009
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-12
- **Final completion:** 2012-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673009, "Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01673009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*